Background: Alopecia areata is a nonscarring hair loss that usually causes round patches of baldness, but alopecia areata incognita (AAI) and diffuse alopecia areata (DAA) can cause a diffuse and acute pattern of hair loss.
Results

Alopecia Areata Incognita
Between April 2012 and April 2017, we diagnosed AAI in 107 patients, of whom 105 were female (98.13%) and only 2 were male; most were Caucasians (97.19%) and the average age was 40.55 years (range 21-79).
Clinical Features
All patients were characterized by increased and diffuse hair thinning without patches, lasting months, and were grouped in 3 degrees of severity as fol- 
Introduction
Alopecia areata (AA) is a common cause of nonscarring hair loss that generally causes round patches of baldness on the scalp, or the whole scalp, or the entire body.
In some patients, however, AA is characterized by a diffuse hair loss, commonly misdiagnosed as telogen effluvium or androgenetic alopecia. The 2 most common variants of nonpatchy AA are alopecia areata incognita (AAI) and diffuse alopecia areata (DAA).
First described by Rebora in 1987 [1] , AAI is more common (about 86%) among young women, especially between 20 and 40 years old [2] . Clinically, it is characterized by widespread and severe hair loss, which develops rapidly in a few weeks in AAI, while DAA can appear over a prolonged period. Currently there are no studies that describe DAA and AAI in a standardized way; therefore, these clinical variants of AA are often not recognized.
The aim of our study is to analyze the clinical, trichoscopic, histological, and therapeutic features of these 2 entities and to underline main differences between them, especially through the aid of trichoscopy and skin biopsy, essential for diagnosis confirmation.
Methods
The study was designed to include data 
Therapy
Therapy was prescribed according to the severity of the disease, pull test, and trichoscopy ( Table 2 ). In particular, clobetasol propionate 0.05% cream under occlusion was prescribed for 69 patients (64.4%) and clobetasol propi- [7] ; an increased number of vellus hairs and miniaturized follicles is also observed, greater than androgenetic alopecia but lower than telogen effluvium [8] . In DAA the widespread The evolution of AA is unpredictable: many cases, especially those affecting less than 40% of the entire scalp, heal spontaneously but recurrences are frequent and often more severe than the onset episode [8] . In our experience, the prognosis for AAI and DDA is generally more favorable than for patchy AA and they do not tend to relapse.
No scientific papers have been published concerning therapeutic approaches and prognosis of AAI, only single-case reports [3, 9] . According to our evidence, both AAI and DAA can be considered benign. In more detail, an improvement was recorded after (Figures 3 and 4) .
The most common trichoscopic sign in both diseases was the presence of empty yellow dots; >5 empty yellow dots in a 40× field were described in 23 patients with DAA (92%) and in only 9 patients with AAI (8.4%), corresponding to the ones with a more severe clinical presentation (grade III).
Our study pointed out also a different distribution of trichoscopy patterns in the 2 diseases: AAI predominately affects parietal-occipital regions whereas DAA manifests itself mainly in was prescribed for treating androgenetic alopecia in 6 patients (24%). Response to therapy was assessed based on the degree of severity of the disease, pull test, and trichoscopy.
Data collected showed that topical steroid therapy was very effective and after 1 year, almost all patients underwent complete remission of DAA (21/22) ( Table 2 ). 
Discussion
